Precision Biosciences Inc (DTIL) Stock Price, Quote & News

Company Profile

Precision BioSciences, Inc., a clinical stage gene editing company, develops in vivo gene editing therapies for gene edits, including gene insertion, excision, and elimination in the United States. The company offers ARCUS, a genome editing platform for DNA genome insertion, removal, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits, as well as to inactivate integrated HBV DNA with t...

Industry: Biotechnology

Sector: Healthcare

Phone: 919 314 5512

Fax: 480 393 5553

Website: precisionbiosciences.com

Address:

302 East Pettigrew St., Suite A-100, Durham, United States

Impatient_Investor Sep. 15 at 6:39 PM

$DTIL best garbage company to lose your money. Not even pump. Slowly raising 50 cents for a month and dump the same within one or two days.

0 · Reply

FloatTommy Sep. 15 at 8:51 AM

$DTIL Positioned to benefit from sector tailwinds; watch execution and margins

0 · Reply

JG101 Sep. 14 at 5:00 AM

$DTIL Recent data presented for first 2 cohorts of patients. So far so good! https://precisionbiosciences.com/wp-content/uploads/2025/09/ICE-HBV-forum_FINAL.pdf

0 · Reply

Impatient_Investor Sep. 12 at 3:31 PM

$DTIL scam company

0 · Reply

Impatient_Investor Sep. 12 at 2:35 PM

$DTIL garbage fell again

0 · Reply

ShurXiJinping Sep. 12 at 11:11 AM

$DTIL

0 · Reply

piton72 Sep. 12 at 11:06 AM

$DTIL Precision BioSciences Presents Data from the Phase 1 E 09/12/2025 - 01:01 PM DURHAM, N.C.--(BUSINESS WIRE)-- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases, today announced that the Company presented clinical data from the Phase 1 ELIMINATE-B trial of PBGENE-HBV in patients with chronic Hepatitis B. The data was presented at the International Coalition to Eliminate HBV (ICE-HBV) “HBV Cure Symposium” Meeting in Berlin, Germany, on September 12th. “We are excited to present the progress for the ELIMINATE-B trial with the HBV community at this year’s ICE-HBV symposium following our data update on August 6th,” said Cassie Gorsuch, PhD, Chief Scientific Officer at Precision BioSciences https://www.stocktitan.net/news/DTIL/precision-bio-sciences-presents-data-from-the-phase-1-eliminate-b-542do9bbxkzl.html

0 · Reply

Thestocktraderhubzee Sep. 8 at 11:16 AM

$DTIL Precision Biosciences To Be Issued Us Patent For PBGENE-HBVARCUS Nuclease Utilized In The Company's Lead In Vivo Gene Editing Program, The Us Patent Will Have An Expiration Date In March 2042

0 · Reply

piton72 Sep. 8 at 11:06 AM

$DTIL - Strengthens the Company’s intellectual property portfolio for lead in vivo program PBGENE-HBV with U.S. patent protection into 2042- - Phase 1 ELIMINATE-B trial progressing through clinical investigation with dosing of Cohort 3 initiated in Third Quarter of 2025- https://www.businesswire.com/news/home/20250908011531/en/Precision-BioSciences-Announces-U.S.-Patent-Covering-PBGENE-HBV-for-Chronic-Hepatitis-B-and-Updates-Program-Status

0 · Reply

JG101 Sep. 4 at 11:20 PM

$DTIL

1 · Reply

Precision BioSciences Presents Data from the Phase 1 ELIMINATE-B Trial of PBGENE-HBV at the 6th International Coalition to Eliminate HBV Cure Symposium

Sep 8, 2025, 7:01 AM EDT - 7 days ago

Precision BioSciences Announces U.S. Patent Covering PBGENE-HBV for Chronic Hepatitis B and Updates Program Status

Aug 7, 2025, 7:01 AM EDT - 5 weeks ago

Precision BioSciences Reports Second Quarter 2025 Financial Results and Provides Business Update

Aug 6, 2025, 7:01 AM EDT - 5 weeks ago

Precision BioSciences Announces Phase 1 Safety and Efficacy for Cohort 1, Lowest Dose Level in ELIMINATE-B, a First-In-Human Trial of PBGENE-HBV for Chronic Hepatitis B

Aug 4, 2025, 7:01 AM EDT - 6 weeks ago

Precision BioSciences to Report Second Quarter 2025 Results on August 7, 2025

Jul 23, 2025, 7:01 AM EDT - 7 weeks ago

Precision BioSciences Receives FDA Orphan Drug Designation for PBGENE-DMD for the Treatment of Duchenne Muscular Dystrophy

Jul 16, 2025, 7:01 AM EDT - 2 months ago

Precision BioSciences Highlights New Preclinical Data for PBGENE-DMD Further Supporting Advancement of Novel Gene Editing Approach for the Treatment of Duchenne Muscular Dystrophy Towards Clinic

Jun 25, 2025, 7:01 AM EDT - 2 months ago

Precision BioSciences Receives FDA Rare Pediatric Disease Designation for PBGENE-DMD for the Treatment of Duchenne Muscular Dystrophy

May 15, 2025, 7:01 AM EDT - 4 months ago

Precision BioSciences Reports First Quarter 2025 Financial Results and Provides Business Update

May 14, 2025, 4:30 PM EDT - 4 months ago

Precision BioSciences Accelerates Development of PBGENE-DMD Within its Wholly Owned Organic Pipeline and Highlights Pre-clinical Evidence at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting

May 8, 2025, 7:01 AM EDT - 4 months ago

Precision BioSciences to Report First Quarter 2025 Results on May 15, 2025

May 7, 2025, 7:01 AM EDT - 4 months ago

Precision BioSciences Announces Presentation of Initial Safety Data from the Phase 1 ELIMINATE-B Trial Evaluating PBGENE-HBV at the 2025 European Association for the Study of the Liver Congress (EASL)

May 1, 2025, 7:01 AM EDT - 4 months ago

Precision BioSciences Announces Multiple Presentations for In Vivo Gene Editing Programs at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting

Apr 29, 2025, 7:00 AM EDT - 4 months ago

Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Apr 15, 2025, 7:01 AM EDT - 5 months ago

Precision BioSciences Receives U.S. FDA Fast Track Designation for PBGENE-HBV, a First-In-Class Gene Editing Therapy Designed to Eliminate the Root Cause of Chronic Hepatitis B

Apr 1, 2025, 7:01 AM EDT - 5 months ago

Precision BioSciences to Participate in the 24th Annual Needham Virtual Healthcare Conference

Mar 26, 2025, 7:01 AM EDT - 6 months ago

Precision BioSciences Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Provides Business Update

Mar 21, 2025, 7:01 AM EDT - 6 months ago

Precision BioSciences to Report Fourth Quarter and Fiscal Year 2024 Results on March 26, 2025

Mar 20, 2025, 7:01 AM EDT - 6 months ago

Precision BioSciences Presents Preclinical Safety and Efficacy Data Supporting Repeat Dosing of PBGENE-HBV With a Goal of Curing Chronic Hepatitis B at the Global Hepatitis Summit 2025

Mar 19, 2025, 7:01 AM EDT - 6 months ago

Precision BioSciences Presents Preclinical Efficacy and Durability Data on PBGENE-DMD for the Treatment of Duchenne Muscular Dystrophy (DMD) at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference

Mar 17, 2025, 7:01 AM EDT - 6 months ago

Precision BioSciences Announces Clearance of Investigational New Drug Application by the U.S. FDA for First-in-Class PBGENE-HBV Designed to Eliminate Root Cause of Chronic Hepatitis B

Mar 12, 2025, 8:00 AM EDT - 6 months ago

iECURE to Present Initial Data from Phase 1/2 OTC-HOPE Clinical Trial in Ornithine Transcarbamylase Deficiency at ACMG Annual Clinical Genetics Meeting

Feb 24, 2025, 7:01 AM EST - 7 months ago

Precision BioSciences Announces Oral Presentation at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference

Feb 19, 2025, 2:27 PM EST - 7 months ago

Precision BioSciences Touts Encouraging Initial Safety And Antiviral Activity Of Hepatitis B Treatment Candidate

Feb 19, 2025, 7:01 AM EST - 7 months ago

Precision BioSciences Announces Initial Safety and Antiviral Activity of PBGENE-HBV in the ELIMINATE-B Clinical Trial

Jan 29, 2025, 7:01 AM EST - 8 months ago

Precision BioSciences Strengthens Senior Leadership Team to Drive Multiple In Vivo Gene Editing Programs

Jan 10, 2025, 2:18 PM EST - 8 months ago

Precision BioSciences' Gene Editing Platform Has Differentiated Mechanism, And Is Potentially Competitive: Analyst

Jan 9, 2025, 10:01 AM EST - 8 months ago

Precision BioSciences Announces Complete Clinical Response in First Infant Dosed by Partner iECURE in Ongoing Phase 1/2 Clinical Trial in Ornithine Transcarbamylase (OTC) Deficiency

Jan 9, 2025, 8:00 AM EST - 8 months ago

iECURE Reports Complete Clinical Response in First Infant Dosed with its In Vivo Gene Editing Candidate ECUR-506 in an Ongoing Phase 1/2 Clinical Trial in Ornithine Transcarbamylase (OTC) Deficiency

Dec 18, 2024, 7:01 AM EST - 9 months ago

Precision BioSciences Receives Approval in Hong Kong to Expand PBGENE-HBV Phase 1 ELIMINATE-B Trial for the Treatment of Chronic Hepatitis B

Nov 21, 2024, 7:01 AM EST - 10 months ago

Precision BioSciences to Participate in Upcoming November Investor Conferences

Nov 15, 2024, 7:00 AM EST - 10 months ago

Precision BioSciences Highlights Preclinical Data and Outlines Design of First-in-Human Clinical Trial for PBGENE-HBV for Treatment of Chronic Hepatitis B

Nov 4, 2024, 7:01 AM EST - 11 months ago

Precision BioSciences Reports Third Quarter 2024 Financial Results and Provides Business Update

Oct 29, 2024, 7:01 AM EDT - 11 months ago

Precision BioSciences to Report Third Quarter Results on November 4, 2024

Oct 28, 2024, 7:01 AM EDT - 11 months ago

Precision BioSciences to Host Virtual Investor Event Highlighting PBGENE-HBV Preclinical Safety Data and Phase 1 Clinical Trial Plans on November 15, 2024

Oct 24, 2024, 4:15 PM EDT - 11 months ago

Precision BioSciences Presents Preclinical Data Highlighting the Capability of ARCUS for High-Efficiency Gene Editing Utilizing Homology-Directed Repair at the ESGCT 31st Annual Congress

Oct 24, 2024, 8:47 AM EDT - 11 months ago

Precision BioSciences Receives First Approval of Clinical Trial Application to Initiate PBGENE-HBV First-In-Human Study for the Treatment of Chronic Hepatitis B

Oct 21, 2024, 7:01 AM EDT - 11 months ago

Precision BioSciences to Participate in Upcoming Longwood Boston CEO and Guggenheim Healthcare Conferences

Oct 16, 2024, 7:01 AM EDT - 11 months ago

Precision BioSciences to Present at the European Society of Gene & Cell Therapy (ESGCT) 31st Annual Congress

Oct 3, 2024, 7:01 AM EDT - 1 year ago

Precision BioSciences to Present at the Upcoming H.C. Wainwright 5th Annual Viral Hepatitis Virtual Conference

Sep 30, 2024, 7:01 AM EDT - 1 year ago

Precision BioSciences Submits First Clinical Trial Applications to Initiate Phase 1 Trial for PBGENE-HBV for the Treatment of Chronic Hepatitis B

Sep 12, 2024, 7:15 AM EDT - 1 year ago

Precision BioSciences Strengthens Senior Leadership Team Ahead of Anticipated PBGENE-HBV Clinical Execution

Sep 4, 2024, 7:01 AM EDT - 1 year ago

Precision BioSciences to Participate in Upcoming H.C. Wainwright 26th Annual Global Healthcare Conference

Sep 3, 2024, 7:01 AM EDT - 1 year ago

Precision BioSciences Receives $13 Million in Proceeds from Imugene Convertible Note Maturity as Part of the August 2023 Azer-cel Deal

Aug 9, 2024, 7:01 AM EDT - 1 year ago

Precision BioSciences Announces Investigational New Drug Clearance by Partner TG Therapeutics for Investigation of Azer-Cel for Multiple Sclerosis

Aug 1, 2024, 7:15 AM EDT - 1 year ago

Precision BioSciences Reports Second Quarter 2024 Financial Results and Provides Business Update

Jul 31, 2024, 7:01 AM EDT - 1 year ago

Precision BioSciences to Participate in Upcoming August Investor Conferences

Jul 29, 2024, 4:15 PM EDT - 1 year ago

Precision BioSciences to Report Second Quarter Results on August 1, 2024

Jul 8, 2024, 7:01 AM EDT - 1 year ago

Precision BioSciences to Present at the Upcoming JonesTrading Healthcare Seaside Summit

Jul 1, 2024, 7:01 AM EDT - 1 year ago

Precision BioSciences Announces its Addition to the Russell Microcap® Index

Impatient_Investor Sep. 15 at 6:39 PM

$DTIL best garbage company to lose your money. Not even pump. Slowly raising 50 cents for a month and dump the same within one or two days.

0 · Reply

FloatTommy Sep. 15 at 8:51 AM

$DTIL Positioned to benefit from sector tailwinds; watch execution and margins

0 · Reply

JG101 Sep. 14 at 5:00 AM

$DTIL Recent data presented for first 2 cohorts of patients. So far so good! https://precisionbiosciences.com/wp-content/uploads/2025/09/ICE-HBV-forum_FINAL.pdf

0 · Reply

Impatient_Investor Sep. 12 at 3:31 PM

$DTIL scam company

0 · Reply

Impatient_Investor Sep. 12 at 2:35 PM

$DTIL garbage fell again

0 · Reply

ShurXiJinping Sep. 12 at 11:11 AM

$DTIL

0 · Reply

piton72 Sep. 12 at 11:06 AM

0 · Reply

Thestocktraderhubzee Sep. 8 at 11:16 AM

$DTIL Precision Biosciences To Be Issued Us Patent For PBGENE-HBVARCUS Nuclease Utilized In The Company's Lead In Vivo Gene Editing Program, The Us Patent Will Have An Expiration Date In March 2042

0 · Reply

piton72 Sep. 8 at 11:06 AM

0 · Reply

JG101 Sep. 4 at 11:20 PM

$DTIL

1 · Reply

Berakhot Sep. 4 at 3:38 PM

$DTIL

0 · Reply

JG101 Sep. 1 at 1:58 PM

$DTIL Fresh off the press!

1 · Reply

Impatient_Investor Aug. 29 at 7:11 PM

$DTIL

1 · Reply

Impatient_Investor Aug. 29 at 3:27 PM

$DTIL in 2050

0 · Reply

Ebrice73 Aug. 29 at 12:26 PM

$DTIL when does this go to $65?

0 · Reply

Impatient_Investor Aug. 29 at 5:56 AM

$DTIL pooch will appear if it raises by 10 cents.

0 · Reply

Impatient_Investor Aug. 27 at 4:42 AM

$DTIL yes, to scam people.

0 · Reply

Impatient_Investor Aug. 26 at 6:19 AM

$DTIL tax loss selling will happen in december

1 · Reply

Scrood_the_Pooch Aug. 25 at 8:03 PM

$DTIL Hey Puka, any idea why this is in that particular session?

1 · Reply

JG101 Aug. 25 at 2:54 PM

$DTIL iECURE, Inc., a genome editing company focused on the development of variant-agnostic in vivo targeted gene insertion therapies for the treatment of liver disorders with significant unmet need, today announced that additional data from the ongoing OTC-HOPE clinical trial evaluating its candidate ECUR-506 in neonatal onset ornithine transcarbamylase (OTC) deficiency will be presented at the 6th International Symposium on Urea Cycle Disorders (UCDs), taking place September 1-2, 2025 in Kyoto, Japan, and the 15th International Congress of Inborn Errors of Metabolism (ICIEM), taking place September 3-6, 2025 in Kyoto, Japan. https://finance.yahoo.com/news/iecure-present-initial-otc-hope-120000886.html?guccounter=1&guce_referrer=aHR0cHM6Ly93d3cuYmluZy5jb20v&guce_referrer_sig=AQAAABtvmwHah8TCJCDFiL2l-PVCPC8MdOdfJviiQ-Lr1q5j_TezcabW4YUTqe5W7yC7VTSsbkhuFUB7jn_jKy5gR1bkKJPHXkjQ__XgNJP5szvSbr0BSCd-3EQhEGVsnqx_uD1eiwC0njbFiljjAs0LIF7wQY_OTaLMEbrzPwcVIZP6

0 · Reply

JVDBNL Aug. 25 at 12:15 PM

$DTIL iECURE to Present Initial OTC-HOPE Clinical Trial Data of ECUR-506 in Ornithine Transcarbamylase Deficiency at 6th International Symposium on UCDs and 15th International Congress of Inborn Errors of Metabolism

0 · Reply

Impatient_Investor Aug. 25 at 7:13 AM

$DTIL this stock has great potential to make you a millionaire....but only when you are a billionaire.

0 · Reply

Market Cap	54.34M
Revenue (ttm)	68.70M
Net Income (ttm)	7.17M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	10.44%
Debt to Equity Ratio	0.66

Volume	61,427
Avg Vol	138,976
Day's Range	N/A - N/A
Shares Out	11.79M
Stochastic %K	16%
Beta	1.61
Analysts	Strong Sell
Price Target	$29.40